Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759000 | 1.00 | MEN1 (0.33) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL22129632 | 1.00 | — | — | |
| SCHEMBL30042650 | 1.00 | MEN1 (0.33) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL9986237 | 1.00 | — | — | |
| SCHEMBL27939 | 1.00 | — | — | |
| SCHEMBL16714239 | 0.94 | ALDH1A1 (0.42) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| Bromide SCHEMBL28697043 | 0.94 | — | — | |
| Ammonia Solution, Strong SCHEMBL1500396 | 0.94 | — | — | |
| SCHEMBL30176793 | 0.89 | ALDH1A1 (0.39) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL1279200 | 0.85 | ALDH1A1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688756-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| CN-119013245-A | Novel compound and organic light emitting device using the same | 株式会社LG化学 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024206347-A1 | FUSED THIADIAZINE DIOXIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024206339-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024206345-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-1999003894-A1 | POLYMERIZABLE COMPOSITIONS CONTAINING ALKOXYAMINE COMPOUNDS DERIVED FROM NITROSO- OR NITRONE COMPOUNDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1999-01-28 | — | — | WO | disclosed |
| EP-0891986-A1 | Polymerizable compositions containing alkoxyamine compounds derived from nitrogen oxide | Ciba SC Holding AG (CH) | 1999-01-20 | — | — | EP | disclosed |
| CN-1193623-A | Substituted purine derivatives, their preparation, their use and compositions containing them | HOECHST AG (DE) | 1998-09-23 | — | — | CN | disclosed |
| CN-1193022-A | Heterocyclic compound used as leucocyte adherence inhibitor and VLA-4 antagonist | HOECHST AG (DE) | 1998-09-16 | — | — | CN | disclosed |
| CN-1187490-A | 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | HOECHST AG (DE) | 1998-07-15 | — | — | CN | disclosed |
| CN-1182746-A | Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | HOECHST AG (DE) | 1998-05-27 | — | — | CN | disclosed |
| US-5714514-A | 2-Cyano-3-mercaptocrotonamides | HOECHST AKTIEGESELLSCHAFT (DE) | 1998-02-03 | — | — | US | disclosed |
| CN-1134696-A | Substituted 5-membered heterocycles, process for their preparation and their use | CASSELLA FARBWERKE MAINKUR AG (DE) | 1996-10-30 | — | — | CN | disclosed |
| US-5455072-A | Initiation and bonding of diamond and other thin films | BENSION ROUVAIN M (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0598361-A1 | Initiation and bonding of diamond and other thin films | Bension, Rouvain M. (US) | 1994-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | MEN1 3354/4885CYP1A2 200/4885CYP3A4 808/4885 |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, COQ8A | MEN1 3354/4885CYP1A2 200/4885CYP3A4 808/4885 |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | MEN1 2683/4885CYP1A2 821/4885CYP3A4 1192/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | MEN1 3559/4885CYP1A2 538/4885CYP3A4 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.